"Antitubercular Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy.
| Descriptor ID |
D000995
|
| MeSH Number(s) |
D27.505.954.122.085.255
|
| Concept/Terms |
Antitubercular Agents- Antitubercular Agents
- Agents, Antitubercular
- Antitubercular Drugs
- Drugs, Antitubercular
- Tuberculostatic Agents
- Agents, Tuberculostatic
|
Below are MeSH descriptors whose meaning is more general than "Antitubercular Agents".
Below are MeSH descriptors whose meaning is more specific than "Antitubercular Agents".
This graph shows the total number of publications written about "Antitubercular Agents" by people in this website by year, and whether "Antitubercular Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 5 | 7 |
| 1996 | 1 | 2 | 3 |
| 1997 | 1 | 2 | 3 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 2 | 0 | 2 |
| 2002 | 5 | 2 | 7 |
| 2003 | 0 | 1 | 1 |
| 2004 | 3 | 2 | 5 |
| 2005 | 2 | 1 | 3 |
| 2006 | 2 | 1 | 3 |
| 2007 | 3 | 0 | 3 |
| 2008 | 5 | 1 | 6 |
| 2009 | 4 | 5 | 9 |
| 2010 | 3 | 2 | 5 |
| 2011 | 7 | 3 | 10 |
| 2012 | 5 | 5 | 10 |
| 2013 | 6 | 4 | 10 |
| 2014 | 9 | 6 | 15 |
| 2015 | 6 | 3 | 9 |
| 2016 | 11 | 9 | 20 |
| 2017 | 15 | 3 | 18 |
| 2018 | 17 | 5 | 22 |
| 2019 | 12 | 4 | 16 |
| 2020 | 9 | 7 | 16 |
| 2021 | 2 | 7 | 9 |
| 2022 | 1 | 11 | 12 |
| 2023 | 1 | 11 | 12 |
| 2024 | 10 | 5 | 15 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antitubercular Agents" by people in Profiles.
-
Strategies to Enhance Diagnostic Capabilities for the New Drug-Resistant Tuberculosis (DR-TB) Drugs. Pathogens. 2024 Nov 28; 13(12).
-
Facilitators and barriers to initiating and completing tuberculosis preventive treatment among children and adolescents living with HIV in Uganda: a qualitative study of adolescents, caretakers and health workers. AIDS Res Ther. 2024 Aug 29; 21(1):59.
-
Understanding the role of video direct observed therapy for patients on an oral short-course regimen for multi-drug resistant tuberculosis: findings from a qualitative study in Eswatini. BMC Infect Dis. 2024 Aug 15; 24(1):829.
-
Bedaquiline: what might the future hold? Lancet Microbe. 2024 Dec; 5(12):100909.
-
Candidate anti-tuberculosis medicines and regimens under clinical evaluation. Clin Microbiol Infect. 2024 Sep; 30(9):1131-1138.
-
Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe: author's response. Clin Microbiol Infect. 2024 Sep; 30(9):1207-1208.
-
The introduction of video-enabled directly observed therapy (video-DOT) for patients with drug-resistant TB disease in Eswatini amid the COVID-19 pandemic - a retrospective cohort study. BMC Health Serv Res. 2024 Jun 03; 24(1):699.
-
Treatment of MDR, Pre-XDR, XDR, and Rifampicin-Resistant Tuberculosis or in Case of Intolerance to at Least Rifampicin in Austria, Germany, and Switzerland. Respiration. 2024; 103(9):593-600.
-
Target regimen profiles for tuberculosis treatment. Bull World Health Organ. 2024 Aug 01; 102(8):600-607.
-
Developing biomarker assays to accelerate tuberculosis drug development: defining target product profiles. Lancet Microbe. 2024 Sep; 5(9):100869.